BridgeBio Oncology Therapeutics (BBOT) Enterprise Value (2024 - 2026)
BridgeBio Oncology Therapeutics (BBOT) posted Enterprise Value of -$252.3 million for Q1 2026, up 40.71% sequentially from -$425.5 million in Q4 2025, and down 26093.11% YoY from N/an in Q1 2025.
BridgeBio Oncology Therapeutics (BBOT) Enterprise Value (2024 - 2026) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Enterprise Value for 3 years, with the latest figure at -$252.3 million in Q1 2026.
- Quarterly Enterprise Value fell 26093.11% year-over-year to -$252.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$252.3 million (down 26093.11% YoY) and the FY2025 annual result came in at -$425.5 million, down 173.38% from the prior year.
- Enterprise Value climbed to -$252.3 million in Q1 2026 per BBOT's latest filing, from -$425.5 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$664231.0 in Q2 2025 and troughed at -$468.3 million in Q3 2025.
- A 3-year average of -$145.4 million and a median of -$1.8 million in 2024 frame the typical range for Enterprise Value.
- The widest YoY moves for Enterprise Value: up 63.39% in 2025, down 26125.11% in 2025.
- Over 3 years, Enterprise Value stood at -$155.6 million in 2024, then sank by 173.38% to -$425.5 million in 2025, then jumped by 40.71% to -$252.3 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$252.3 million, -$425.5 million, and -$468.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | BridgeBio Oncology Therapeutics | 726.38 Mn | 500.67 Mn | - | -225.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -225.71 Mn |
| Mar 31, 2026 | -252.28 Mn |
| Dec 31, 2025 | -425.46 Mn |
| Sep 30, 2025 | -468.29 Mn |
| Jun 30, 2025 | -664,231.00 |
| Mar 31, 2025 | -963,135.00 |
| Dec 31, 2024 | -155.63 Mn |
| Sep 30, 2024 | -1.79 Mn |
| Jun 30, 2024 | -1.81 Mn |
| Mar 31, 2024 | -1.84 Mn |